Max Nisen is a Bloomberg Gadfly columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.

This could be the most exciting time in cancer-research history; previously deadly diseases may be survivable for some patients. But there’s a cost. The first approved combination of immune-oncology drugs -- immunity-boosting medicines that can produce spectacular results -- is priced at an incredible $256,000 a year in the U.S. Discounts and rebates usually cut the actual prices people pay for such drugs. But cancer drugs often aren’t discounted as much as other medicines. Even with discounts, the U.S. pays far more for cancer drugs than other countries. A wave of new medicines will likely make the price divide between the U.S and the rest of the world even worse, and may make cancer the center of the next big drug-pricing fights. Click on the video below to see more.

Cancer Drugs Are Headed for a Price Cut

This column does not necessarily reflect the opinion of Bloomberg LP and its owners.

To contact the author of this story:
Max Nisen in New York at

To contact the editor responsible for this story:
Mark Gongloff at